Glutathione in cancer cell death

Cancers

Volumn 3, Issue 1, 2011, Pages 1285-1310

  Ortega, Angel L ^a   Mena, Salvador ^b   Estrela, Jose M ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Green Molecular SL   (Spain)

Author keywords

Apoptosis; Autophagy; Cancer; Cell death; Glutathione; Necrosis

Indexed keywords

ACIVICIN; ALOE EMODIN; AMINOSYN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; APOPTOSOME; BUTHIONINE SULFOXIMINE; CYTOTOXIC AGENT; DENBINOBIN; FLAVONOID; GALLIC ACID PROPYL ESTER; GLUTAMINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; OBLIMERSEN; PACLITAXEL; REACTIVE OXYGEN METABOLITE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINCA ALKALOID; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; DIARRHEA; DIET SUPPLEMENTATION; DNA SYNTHESIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; INFECTION; LIVER CANCER; LIVER VENOOCCLUSIVE DISEASE; LUNG CANCER; LYMPHOMA; MELANOMA; MITOCHONDRIAL PERMEABILITY; MUCOSA INFLAMMATION; MYELOMA; NEUROPATHY; NONHUMAN; OVARY CANCER; OXIDATION REDUCTION STATE; PROTEIN EXPRESSION; PROTEIN PROCESSING; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STOMACH CANCER;

EID: 79953715374     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3011285     Document Type: Review

References (182)

1. Bignold, L.P.; Coghlan, B.L.; Jersmann, H.P. Cancer morphology, carcinogenesis and genetic instability: A background. E X S 2006, 1-24.
2. Meister, A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. P harm acol. Ther. 1991, 51, 155-194.
3. Ames, B.N.; Gold, L.S.; Willett, W.C. The causes and prevention of cancer. Proc. Natl. Acad. Sci. U SA 1995, 92, 5258-5265.
4. Conway, J.G.; Neptun, D.A.; Garvey, L.K.; Popp, J.A. Carcinogen treatment increases glutathione hydrolysis by gamma-glutamyl transpeptidase. C a r ci no genesis 1987, 8, 999-1004.
5. Crook, T.R.; Souhami, R.L.; Whyman, G.D.; McLean, A.E. Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide. C an c e r Re s. 1986, 46, 5035-5038.
6. DeGraff, W.G.; Russo, A.; Mitchell, J.B. Glutathione depletion greatly reduces neocarzinostatin cytotoxicity in chinese hamster v79 cells. J. B iol. C hem. 1985, 260, 8312-8315.
7. Mitchell, J.B.; Russo, A. The role of glutathione in radiation and drug induced cytotoxicity. B r. J. Cancer Suppl. 1987, 8, 96-104.
8. Bump, E.A.; Brown, J.M. Role of glutathione in the radiation response of mammalian cells in vitro and in vivo. Pharmacol. Ther. 1990, 47, 117-136.
9. Estrela, J.M.; Obrador, E.; Navarro, J.; Lasso De la Vega, M.C.; Pellicer, J.A. Elimination of ehrlich tumours by atp-induced growth inhibition, glutathione depletion and x-rays. N at. M ed. 1995, 1, 84-88.
10. Mena, S.; Benlloch, M.; Ortega, A.; Carretero, J.; Obrador, E.; Asensi, M.; Petschen, I.; Brown, B.D.; Estrela, J.M. Bcl-2 and glutathione depletion sensitizes b16 melanoma to combination therapy and eliminates metastatic disease. C li n. Can cer R es. 2007, 13, 2658-2666.
11. Obrador, E.; Carretero, J.; Esteve, J.M.; Pellicer, J.A.; Pascual, A.; Petschen, I.; Estrela, J.M. Glutamine potentiates tnf-alpha-induced tumor cytotoxicity. F r ee R a di c. B io l. M ed. 2001, 31, 642-650.
12. Um, J.H.; Kwon, J.K.; Kang, C.D.; Kim, M.J.; Ju, D.S.; Bae, J.H.; Kim, D.W.; Chung, B.S.; Kim, S.H. Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. J. Pharmacol. Exp. Ther. 2004, 311, 1062-1070.
13. Suthanthiran, M.; Anderson, M.E.; Sharma, V.K.; Meister, A. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human t lymphocytes stimulated via the cd2 and cd3 antigens. Proc. Natl. Acad. Sci. USA 1990, 87, 3343-3347.
14. Terradez, P.; Asensi, M.; Lasso de la Vega, M.C.; Puertes, I.R.; Vina, J.; Estrela, J.M. Depletion of tumour glutathione in vivo by buthionine sulphoximine: Modulation by the rate of cellular proliferation and inhibition of cancer growth. Biochem. J. 1993, 292 (Pt. 2), 477-483.
15. Yao, K.S.; Godwin, A.K.; Johnson, S.W.; Ozols, R.F.; O'Dwyer, P.J.; Hamilton, T.C. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatinsensitive and cisplatin-resistant human ovarian cancer cell lines. C an c e r R es. 1995, 55, 4367-4374.
16. Ortega, A.; Carretero, J.; Obrador, E.; Estrela, J.M. Tumoricidal activity of endothelium-derived no and the survival of metastatic cells with high gsh and bcl-2 levels. N it r i c. Oxi d e 2008, 19, 107-114.
17. Obrador, E.; Carretero, J.; Ortega, A.; Medina, I.; Rodilla, V.; Pellicer, J.A.; Estrela, J.M. Gamma-glutamyl transpeptidase overexpression increases metastatic growth of b 16 melanoma cells in the mouse liver. H epato logy 2002, 35, 74-81.
18. Ortega, A.; Mena, S.; Estrela, J.M. Oxidative and nitrosative stress in the metastatic microenvironment. Cancers 2010, 2, 274-304.
19. Franco, R.; Sanchez-Olea, R.; Reyes-Reyes, E.M.; Panayiotidis, M.I. Environmental toxicity, oxidative stress and apoptosis: Menage a trois. M utat. Res. 2009, 674, 3-22.
20. Carretero, J.; Obrador, E.; Anasagasti, M.J.; Martin, J.J.; Vidal-Vanaclocha, F.; Estrela, J.M. Growth-associated changes in glutathione content correlate with liver metastatic activity of b 16 melanoma cells. Clin. Exp. M etastas. 1999, 17, 567-574.
21. Lai, G.M.; Moscow, J.A.; Alvarez, M.G.; Fojo, A.T.; Bates, S.E. Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. Int. J. Cancer 1991, 49, 688-695.
22. Calvert, P.; Yao, K.S.; Hamilton, T.C.; O'Dwyer, P.J. Clinical studies of reversal of drug resistance based on glutathione. C hem. B io l. I n ter act. 1998, 111-112, 213-224.
23. Arrick, B.A.; Nathan, C.F. Glutathione metabolism as a determinant of therapeutic efficacy: A review. Cancer Res. 1984, 44, 4224-4232.
24. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of atp-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
25. Estrela, J.M.; Ortega, A.; Obrador, E. Glutathione in cancer biology and therapy. C r it. Rev. C li n. Lab. Sci. 2006, 43, 143-181.
26. Meister, A. Selective modification of glutathione metabolism. Science 1983, 220, 472-477.
27. Krebs, H.A.; Gascoyne, T. The redox state of the nicotinamide-adenine dinucleotides in rat liver homogenates. Biochem. J. 1968, 108, 513-520.
28. Rebrin, I.; Sohal, R.S. Comparison of thiol redox state of mitochondria and homogenates of various tissues between two strains of mice with different longevities. Exp. G erontol. 2004, 39, 1513-1519.
29. Halliwell, B. Oxidants and human disease: Some new concepts. F aseb J. 1987, 1, 358-364.
30. Valko, M.; Morris, H.; Cronin, M.T. Metals, toxicity and oxidative stress. Curr. Med. C hem. 2005, 12, 1161-1208.
31. Halliwell, B.; Gutteridge, J.M. The definition and measurement of antioxidants in biological systems. Free Radic. Biol. Med. 1995, 18, 125-126.
32. Priego, S.; Feddi, F.; Ferrer, P.; Mena, S.; Benlloch, M.; Ortega, A.; Carretero, J.; Obrador, E.; Asensi, M.; Estrela, J.M. Natural polyphenols facilitate elimination of ht-29 colorectal cancer xenografts by chemoradiotherapy: A bcl-2-and superoxide dismutase 2-dependent mechanism. M ol. Cancer Ther. 2008, 7, 3330-3342.
33. Loschen, G.; Flohe, L.; Chance, B. Respiratory chain linked h(2)o(2) production in pigeon heart mitochondria. FEBS Lett. 1971, 18, 261-264.
34. Pastor, N.; Weinstein, H.; Jamison, E.; Brenowitz, M. A detailed interpretation of oh radical footprints in a tbp-DNA complex reveals the role of dynamics in the mechanism of sequence-specific binding. J. M ol. Biol. 2000, 304, 55-68.
35. Burcham, P.C. Genotoxic lipid peroxidation products: Their DNA damaging properties and role in formation of endogenous DNA adducts. M utagenesis 1998, 13, 287-305.
36. Shacter, E.; Weitzman, S.A. Chronic inflammation and cancer. Oncology (Williston Park) 2002, 16, 217-226, 229, discussion 230-212.
37. Terasaki, Y.; Akuta, T.; Terasaki, M.; Sawa, T.; Mori, T.; Okamoto, T.; Ozaki, M.; Takeya, M.; Akaike, T. Guanine nitration in idiopathic pulmonary fibrosis and its implication for carcinogenesis. Am. J. R esp i r. C r it. C are M ed. 2006, 174, 665-673.
38. Szabo, C.; Ohshima, H. DNA damage induced by peroxynitrite: Subsequent biological effects. Nitric. Oxide 1997, 1, 373-385.
39. Boveris, A.; Chance, B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem. J. 1973, 134, 707-716.
40. Park, W.H.; Han, Y.W.; Kim, S.H.; Kim, S.Z. An ros generator, antimycin a, inhibits the growth of hela cells via apoptosis. J. Cell Biochem. 2007, 102, 98-109.
41. Ischiropoulos, H.; Beckman, J.S. Oxidative stress and nitration in neurodegeneration: Cause, effect, or association? J. Cli n. Invest. 2003, 111, 163-169.
42. Mieyal, J.J.; Gallogly, M.M.; Qanungo, S.; Sabens, E.A.; Shelton, M.D. Molecular mechanisms and clinical implications of reversible protein s-glutathionylation. Ant io xi d. Redo x Signal. 2008, 10, 1941-1988.
43. Federico, A.; Morgillo, F.; Tuccillo, C.; Ciardiello, F.; Loguercio, C. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer 2007, 121, 2381-2386.
44. Ekshyyan, O.; Aw, T.Y. Decreased susceptibility of differentiated pc12 cells to oxidative challenge: Relationship to cellular redox and expression of apoptotic protease activator factor-1. Cell Death Difer. 2005, 12, 1066-1077.
45. Hara, M.R.; Snyder, S.H. Cell signaling and neuronal death. Ann u. Rev. P ha r m a c ol. Toxic o l. 2007, 47, 117-141.
46. Higuchi, Y.; Yoshimoto, T. Arachidonic acid converts the glutathione depletion-induced apoptosis to necrosis by promoting lipid peroxidation and reducing caspase-3 activity in rat glioma cells. Arch. Biochem. Biophys. 2002, 400, 133-140.
47. Klionsky, D.J. Autophagy. Curr. Biol. 2005, 15, R282-283.
48. de Bruin, E.C.; Medema, J.P. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat. Rev. 2008, 34, 737-749.
49. Kuranaga, E.; Miura, M. Nonapoptotic functions of caspases: Caspases as regulatory molecules for immunity and cell-fate determination. Trends Cell B iol. 2007, 17, 135-144.
50. Pennington, J.D.; Wang, T.J.; Nguyen, P.; Sun, L.; Bisht, K.; Smart, D.; Gius, D. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy. D rug Resist. U pd ate s 2005, 8, 322-330.
51. Rahman, I.; Marwick, J.; Kirkham, P. Redox modulation of chromatin remodeling: Impact on histone acetylation and deacetylation, nf-kappab and pro-inflammatory gene expression. B io c hem. Pharmacol. 2004, 68, 1255-1267.
52. Higuchi, Y. Glutathione depletion-induced chromosomal DNA fragmentation associated with apoptosis and necrosis. J. Cell M ol. Med. 2004, 8, 455-464.
53. Hall, A.G. Review: The role of glutathione in the regulation of apoptosis. E u r. J. C li n. I n vest. 1999, 29, 238-245.
54. Hall, A.G. Glutathione and the regulation of cell death. A dv. E xp. M ed. B io l. 1999, 457, 199-203.
55. Kretz-Remy, C.; Arrigo, A.P. Gene expression and thiol redox state. M et hod s E n zy m ol. 2002, 348, 200-215.
56. Balendiran, G.K.; Dabur, R.; Fraser, D. The role of glutathione in cancer. C ell B io c hem. F u n ct. 2004, 22, 343-352.
57. Janssen-Heininger, Y.M.; Aesif, S.W.; van der Velden, J.; Guala, A.S.; Reiss, J.N.; Roberson, E.C.; Budd, R.C.; Reynaert, N.L.; Anathy, V. Regulation of apoptosis through cysteine oxidation: Implications for fibrotic lung disease. Ann. N Y A cad. Sci. 2010, 1203, 23-28.
58. Kensler, T.W.; Wakabayashi, N.; Biswal, S. Cell survival responses to environmental stresses via the keap1-nrf2-are pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 89-116.
59. Arrigo, A.P. Gene expression and the thiol redox state. Free Rad i c. B i ol. M ed. 1999, 27, 936-944.
60. D'Alessio, M.; Cerella, C.; Amici, C.; Pesce, C.; Coppola, S.; Fanelli, C.; De Nicola, M.; Cristofanon, S.; Clavarino, G.; Bergamaschi, A.; Magrini, A.; Gualandi, G.; Ghibelli, L. Glutathione depletion up-regulates bcl-2 in bso-resistant cells. F A SE B J. 2004, 18, 1609-1611.
61. Song, J.J.; Lee, Y.J. Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal-regulating kinase 1. B ioc hem. J. 2003, 373, 845-853.
62. Jones, D.P. Redox sensing: Orthogonal control in cell cycle and apoptosis signalling. J. I nter n. M ed. 2010, 268, 432-448.
63. Morales, A.; Miranda, M.; Sanchez-Reyes, A.; Biete, A.; Fernandez-Checa, J.C. Oxidative damage of mitochondrial and nuclear DNA induced by ionizing radiation in human hepatoblastoma cells. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42, 191-203.
64. Friesen, C.; Kiess, Y.; Debatin, K.M. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Difer. 2004, 11 (Suppl. 1), S73-85.
65. Cazanave, S.; Berson, A.; Haouzi, D.; Vadrot, N.; Fau, D.; Grodet, A.; Letteron, P.; Feldmann, G.; El-Benna, J.; Fromenty, B.; Robin, M.A.; Pessayre, D. High hepatic glutathione stores alleviate fas-induced apoptosis in mice. J. H epatol. 2007, 46, 858-868.
66. Armstrong, J.S.; Steinauer, K.K.; Hornung, B.; Irish, J.M.; Lecane, P.; Birrell, G.W.; Peehl, D.M.; Knox, S.J. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human b lymphoma cell line. C ell D eath D ifer. 2002, 9, 252-263.
67. Tormos, C.; Javier Chaves, F.; Garcia, M.J.; Garrido, F.; Jover, R.; O'Connor, J.E.; Iradi, A.; Oltra, A.; Oliva, M.R.; Saez, G.T. Role of glutathione in the induction of apoptosis and c-fos and c-jun mrnas by oxidative stress in tumor cells. Cancer Lett. 2004, 208, 103-113.
68. Franco, R.; Panayiotidis, M.I.; Cidlowski, J.A. Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation. J. B iol. C hem. 2007, 282, 30452-30465.
69. Wang, X.; Cederbaum, A.I. S-adenosyl-l-methionine attenuates hepatotoxicity induced by agonistic jo2 fas antibody following cyp2e 1 induction in mice. J. P harm a col. E x p. The r. 2006, 317, 44-52.
70. Brdiczka, D.G.; Zorov, D.B.; Sheu, S.S. Mitochondrial contact sites: Their role in energy metabolism and apoptosis. Biochim. Biophys. Acta 2006, 1762, 148-163.
71. Gogvadze, V.; Orrenius, S.; Zhivotovsky, B. Multiple pathways of cytochrome c release from mitochondria in apoptosis. Biochim. Biophys. Acta 2006, 1757, 639-647.
72. Troyano, A.; Sancho, P.; Fernandez, C.; de Blas, E.; Bernardi, P.; Aller, P. The selection between apoptosis and necrosis is differentially regulated in hydrogen peroxide-treated and glutathionedepleted human promonocytic cells. Cell Death Difer. 2003, 10, 889-898.
73. Kokoszka, J.E.; Waymire, K.G.; Levy, S.E.; Sligh, J.E.; Cai, J.; Jones, D.P.; MacGregor, G.R.; Wallace, D.C. The adp/atp translocator is not essential for the mitochondrial permeability transition pore. Nature 2004, 427, 461-465.
74. Krauskopf, A.; Eriksson, O.; Craigen, W.J.; Forte, M.A.; Bernardi, P. Properties of the permeability transition in vdac1(-/-) mitochondria. B i och i m. B i ophys. Acta 2006, 1757, 590-595.
75. Baines, C.P.; Kaiser, R.A.; Sheiko, T.; Craigen, W.J.; Molkentin, J.D. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. N at. Cell B iol. 2007, 9, 550-555.
76. Beatrice, M.C.; Stiers, D.L.; Pfeiffer, D.R. The role of glutathione in the retention of ca2+ by liver mitochondria. J. Biol. C hem. 1984, 259, 1279-1287.
77. Petronilli, V.; Costantini, P.; Scorrano, L.; Colonna, R.; Passamonti, S.; Bernardi, P. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents. J. Biol. Chem. 1994, 269, 16638-16642.
78. Costantini, P.; Chernyak, B.V.; Petronilli, V.; Bernardi, P. Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J. Biol. Chem. 1996, 271, 6746-6751.
79. Halestrap, A.P.; Woodfield, K.Y.; Connern, C.P. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J. B io l. C hem. 1997, 272, 3346-3354.
80. Costantini, P.; Colonna, R.; Bernardi, P. Induction of the mitochondrial permeability transition by n-ethylmaleimide depends on secondary oxidation of critical thiol groups. Potentiation by copperortho-phenanthroline without dimerization of the adenine nucleotide translocase. B io c hi m. Biophys. Acta 1998, 1365, 385-392.
81. Kowaltowski, A.J.; Castilho, R.F.; Vercesi, A.E. Mitochondrial permeability transition and oxidative stress. FEBS Lett. 2001, 495, 12-15.
82. Mena, S.; Ortega, A.; Estrela, J.M. Oxidative stress in environmental-induced carcinogenesis. M utat. Res. 2009, 674, 36-44.
83. Guha, P.; Dey, A.; Sen, R.; Chatterjee, M.; Chattopadhyay, S.; Bandyopadhyay, S.K. Intracellular gsh depletion triggered mitochondrial bax translocation to accomplish resveratrol-induced apoptosis in the u937 cell line. J. Pharmacol. Exp. Ther. 336, 206-214.
84. Dalton, T.P.; Chen, Y.; Schneider, S.N.; Nebert, D.W.; Shertzer, H.G. Genetically altered mice to evaluate glutathione homeostasis in health and disease. F r ee R ad i c. B io l. M ed. 2004, 37, 1511-1526.
85. Armstrong, J.S.; Whiteman, M.; Yang, H.; Jones, D.P.; Sternberg, P., Jr. Cysteine starvation activates the redox-dependent mitochondrial permeability transition in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 2004, 45, 4183-4189.
86. Circu, M.L.; Aw, T.Y. Glutathione and apoptosis. F ree Radic. Res. 2008, 42, 689-706.
87. Franco, R.; Schoneveld, O.J.; Pappa, A.; Panayiotidis, M.I. The central role of glutathione in the pathophysiology of human diseases. Arch. Physiol. Biochem. 2007, 113, 234-258.
88. Franco, R.; Cidlowski, J.A. Apoptosis and glutathione: Beyond an antioxidant. C ell D eath D ifer. 2009, 16, 1303-1314.
89. Honda, T.; Coppola, S.; Ghibelli, L.; Cho, S.H.; Kagawa, S.; Spurgers, K.B.; Brisbay, S.M.; Roth, J.A.; Meyn, R.E.; Fang, B.; McDonnell, T.J. Gsh depletion enhances adenoviral bax-induced apoptosis in lung cancer cells. C ancer Gene Ther. 2004, 11, 249-255.
90. Guha, P.; Dey, A.; Dhyani, M.V.; Sen, R.; Chatterjee, M.; Chattopadhyay, S.; Bandyopadhyay, S.K. Calpain and caspase orchestrated death signal to accomplish apoptosis induced by resveratrol and its novel analog hydroxystilbene-1 [correction of hydroxstilbene-1] in cancer cells. J. Pharmacol. Exp. Ther. 2010, 334, 381-394.
91. Paget, M.S.; Kang, J.G.; Roe, J.H.; Buttner, M.J. Sigmar, an rna polymerase sigma factor that modulates expression of the thioredoxin system in response to oxidative stress in streptomyces coelicolor a3(2). Embo. J. 1998, 17, 5776-5782.
92. Parmentier, M.; Hirani, N.; Rahman, I.; Donaldson, K.; MacNee, W.; Antonicelli, F. Regulation of lipopolysaccharide-mediated interleukin-1beta release by n-acetylcysteine in thp-1 cells. Eu r. Respir. J. 2000, 16, 933-939.
93. Usatyuk, P.V.; Parinandi, N.L.; Natarajan, V. Redox regulation of 4-hydroxy-2-nonenal-mediated endothelial barrier dysfunction by focal adhesion, adherens, and tight junction proteins. J. B io l. Chem. 2006, 281, 35554-35566.
94. Biswas, S.K.; Rahman, I. Environmental toxicity, redox signaling and lung inflammation: The role of glutathione. M ol. Aspects Med. 2009, 30, 60-76.
95. Erickson, A.M.; Nevarea, Z.; Gipp, J.J.; Mulcahy, R.T. Identification of a variant antioxidant response element in the promoter of the human glutamate-cysteine ligase modifier subunit gene. Revision of the are consensus sequence. J. B io l. C hem. 2002, 277, 30730-30737.
96. Harper, R.; Wu, K.; Chang, M.M.; Yoneda, K.; Pan, R.; Reddy, S.P.; Wu, R. Activation of nuclear factor-kappa b transcriptional activity in airway epithelial cells by thioredoxin but not by n-acetyl-cysteine and glutathione. Am. J. R esp i r. Cell M ol. B io l. 2001, 25, 178-185.
97. Dickinson, D.A.; Iles, K.E.; Zhang, H.; Blank, V.; Forman, H.J. Curcumin alters epre and ap-1 binding complexes and elevates glutamate-cysteine ligase gene expression. FASEB J. 2003, 17, 473-475.
98. Wild, A.C.; Moinova, H.R.; Mulcahy, R.T. Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor nrf2. J. B io l. C hem. 1999, 274, 33627-33636.
99. Hayes, J.D.; McLellan, L.I. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Rad i c. R es. 1999, 31, 273-300.
100. Chanas, S.A.; Jiang, Q.; McMahon, M.; McWalter, G.K.; McLellan, L.I.; Elcombe, C.R.; Henderson, C.J.; Wolf, C.R.; Moffat, G.J.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Loss of the nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione s-transferase gsta1, gsta2, gstm1, gstm2, gstm3 and gstm4 genes in the livers of male and female mice. B iochem. J. 2002, 365, 405-416.
101. Morito, N.; Yoh, K.; Itoh, K.; Hirayama, A.; Koyama, A.; Yamamoto, M.; Takahashi, S. Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels. Oncogene 2003, 22, 9275-9281.
102. Nguyen, T.; Sherratt, P.J.; Pickett, C.B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. A nnu. Rev. P harm acol. Toxicol. 2003, 43, 233-260.
103. Hansen, J.M.; Watson, W.H.; Jones, D.P. Compartmentation of nrf-2 redox control: Regulation of cytoplasmic activation by glutathione and DNA binding by thioredoxin-1. Toxi col. Sc i. 2004, 82, 308-317.
104. Lee, K.S.; Kim, S.R.; Park, H.S.; Park, S.J.; Min, K.H.; Lee, K.Y.; Choe, Y.H.; Hong, S.H.; Han, H.J.; Lee, Y.R.; Kim, J.S.; Atlas, D.; Lee, Y.C. A novel thiol compound, n-acetylcysteine amide, attenuates allergic airway disease by regulating activation of nf-kappab and hypoxia-inducible factor-1alpha. Exp. M ol. Med. 2007, 39, 756-768.
105. Chen, C.H.; Lin, W.C.; Kuo, C.N.; Lu, F.J. Role of redox signaling regulation in propyl gallateinduced apoptosis of human leukemia cells. Food C hem. Toxicol. 2011, 49, 494-501.
106. Kuo, C.T.; Chen, B.C.; Yu, C.C.; Weng, C.M.; Hsu, M.J.; Chen, C.C.; Chen, M.C.; Teng, C.M.; Pan, S.L.; Bien, M.Y.; Shih, C.H.; Lin, C.H. Apoptosis signal-regulating kinase 1 mediates denbinobin-induced apoptosis in human lung adenocarcinoma cells. J. B io med. Sci. 2009, 16, 43.
107. Lu, G.D.; Shen, H.M.; Chung, M.C.; Ong, C.N. Critical role of oxidative stress and sustained jnk activation in aloe-emodin-mediated apoptotic cell death in human hepatoma cells. C a r ci no genesis 2007, 28, 1937-1945.
108. Levine, B.; Kroemer, G. Autophagy in the pathogenesis of disease. C ell 2008, 132, 27-42.
109. Kroemer, G.; Galluzzi, L.; Vandenabeele, P.; Abrams, J.; Alnemri, E.S.; Baehrecke, E.H.; Blagosklonny, M.V.; El-Deiry, W.S.; Golstein, P.; Green, D.R.; Hengartner, M.; Knight, R.A.; Kumar, S.; Lipton, S.A.; Malorni, W.; Nunez, G.; Peter, M.E.; Tschopp, J.; Yuan, J.; Piacentini, M.; Zhivotovsky, B.; Melino, G. Classification of cell death: Recommendations of the nomenclature committee on cell death 2009. C ell D eat h D i fe r. 2009, 16, 3-11.
110. Scherz-Shouval, R.; Shvets, E.; Fass, E.; Shorer, H.; Gil, L.; Elazar, Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of atg4. E m b o. J. 2007, 26, 1749-1760.
111. Yuan, H.; Perry, C.N.; Huang, C.; Iwai-Kanai, E.; Carreira, R.S.; Glembotski, C.C.; Gottlieb, R.A. Lps-induced autophagy is mediated by oxidative signaling in cardiomyocytes and is associated with cytoprotection. Am. J. Physiol. H eart Circ. Physiol. 2009, 296, H470-H479.
112. Azad, M.B.; Chen, Y.; Gibson, S.B. Regulation of autophagy by reactive oxygen species (ros): Implications for cancer progression and treatment. Ant io xi d. Redo x Signal. 2009, 11, 777-790.
113. Son, M.J.; Lee, S.B.; Byun, Y.J.; Lee, H.O.; Kim, H.S.; Kwon, O.J.; Jeong, S.W. Sodium nitroprusside induces autophagic cell death in glutathione-depleted osteoblasts. J. B io c hem. M ol. Toxicol. 2010, 24, 313-322.
114. Chen, Y.; Gibson, S.B. Is mitochondrial generation of reactive oxygen species a trigger for autophagy? Autophagy 2008, 4, 246-248.
115. Zong, W.X.; Thompson, C.B. Necrotic death as a cell fate. Genes D ev. 2006, 20, 1-15.
116. Obrador, E.; Carretero, J.; Pellicer, J.A.; Estrela, J.M. Possible mechanisms for tumour cell sensitivity to tnf-alpha and potential therapeutic applications. C u r r. P harm. B io technol. 2001, 2, 119-130.
117. Dethmers, J.K.; Meister, A. Glutathione export by human lymphoid cells: Depletion of glutathione by inhibition of its synthesis decreases export and increases sensitivity to irradiation. Proc. Natl. Acad. Sci. USA 1981, 78, 7492-7496.
118. Moscow, J.A.; Dixon, K.H. Glutathione-related enzymes, glutathione and multidrug resistance. Cytotechnology 1993, 12, 155-170.
119. Mistry, P.; Harrap, K.R. Historical aspects of glutathione and cancer chemotherapy. P harm a c ol. Ther. 1991, 49, 125-132.
120. Gatti, L.; Zunino, F. Overview of tumor cell chemoresistance mechanisms. M et hod s M ol. M ed. 2005, 111, 127-148.
121. Wijnholds, J. Drug resistance caused by multidrug resistance-associated proteins. N ova r t is F o u n d. Symp. 2002, 243, 69-79; discussion 80-62, 180-185.
122. Zhou, S.F. Structure, function and regulation of p-glycoprotein and its clinical relevance in drug disposition. Xenobi oti ca 2008, 38, 802-832.
123. Baguley, B.C. Multidrug resistance in cancer. Methods M ol. Biol. 2010, 596, 1-14.
124. Zaman, G.J.; Lankelma, J.; van Tellingen, O.; Beijnen, J.; Dekker, H.; Paulusma, C.; Oude Elferink, R.P.; Baas, F.; Borst, P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. P r o c. N at l. A cad. Sc i. U SA 1995, 92, 7690-7694.
125. Rappa, G.; Lorico, A.; Flavell, R.A.; Sartorelli, A.C. Evidence that the multidrug resistance protein (mrp) functions as a co-transporter of glutathione and natural product toxins. C ancer Res. 1997, 57, 5232-5237.
126. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: The multidrug resistance-associated proteins. J. Nat. Cancer Inst. 2000, 92, 1295-1302.
127. Cole, S.P.; Deeley, R.G. Transport of glutathione and glutathione conjugates by mrp1. Trends Pharmacol. Sci. 2006, 27, 438-446.
128. Ballatori, N.; Krance, S.M.; Marchan, R.; Hammond, C.L. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. M ol. Aspects M ed. 2009, 30, 13-28.
129. Reisman, S.A.; Csanaky, I.L.; Yeager, R.L.; Klaassen, C.D. Nrf2 activation enhances biliary excretion of sulfobromophthalein by inducing glutathione-s-transferase activity. Toxic o l. Sc i. 2009, 109, 24-30.
130. Keppler, D. Multidrug resistance proteins (mrps, abccs): Importance for pathophysiology and drug therapy. H andb. Exp. P harm acol. 2011, 201, 299-323.
131. Maher, J.M.; Dieter, M.Z.; Aleksunes, L.M.; Slitt, A.L.; Guo, G.; Tanaka, Y.; Scheffer, G.L.; Chan, J.Y.; Manautou, J.E.; Chen, Y.; Dalton, T.P.; Yamamoto, M.; Klaassen, C.D. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-e2-related factor-2 transcriptional pathway. H epatology 2007, 46, 1597-1610.
132. Klaassen, C.D.; Reisman, S.A. Nrf2 the rescue: Effects of the antioxidative/electrophilic response on the liver. Toxicol. Appl. Pharmacol. 2010, 244, 57-65.
133. Leslie, E.M.; Deeley, R.G.; Cole, S.P. Multidrug resistance proteins: Role of p-glycoprotein, mrp1, mrp2, and bcrp (abcg2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204, 216-237.
134. Depeille, P.; Cuq, P.; Passagne, I.; Evrard, A.; Vian, L. Combined effects of gstp1 and mrp1 in melanoma drug resistance. B r. J. C an c e r 2005, 93, 216-223.
135. Versantvoort, C.H.; Broxterman, H.J.; Bagrij, T.; Scheper, R.J.; Twentyman, P.R. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpres sing multidrug resistance-associated protein. Br. J. Can cer 1995, 72, 82-89.
136. Schneider, E.; Yamazaki, H.; Sinha, B.K.; Cowan, K.H. Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer mcf7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation. B r. J. C an c e r 1995, 71, 738-743.
137. Lorico, A.; Rappa, G.; Finch, R.A.; Yang, D.; Flavell, R.A.; Sartorelli, A.C. Disruption of the murine mrp (multidrug resistance protein) gene leads to increased sensitivity to etoposide (vp-16) and increased levels of glutathione. C ancer Res. 1997, 57, 5238-5242.
138. Loe, D.W.; Deeley, R.G.; Cole, S.P. Verapamil stimulates glutathione transport by the 190-kda multidrug resistance protein 1 (mrp 1). J. P harm a col. E x p. The r. 2000, 293, 530-538.
139. Leslie, E.M.; Deeley, R.G.; Cole, S.P. Bioflavonoid stimulation of glutathione transport by the 190-kda multidrug resistance protein 1 (mrp 1). D r u g M eta b. D ispo s. 2003, 31, 11-15.
140. Loe, D.W.; Deeley, R.G.; Cole, S.P. Characterization of vincristine transport by the m(r) 190,000 multidrug resistance protein (mrp): Evidence for cotransport with reduced glutathione. C ancer Res. 1998, 58, 5130-5136.
141. Benlloch, M.; Ortega, A.; Ferrer, P.; Segarra, R.; Obrador, E.; Asensi, M.; Carretero, J.; Estrela, J.M. Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic b 16 melanoma cells to endothelium-induced cytotoxicity. J. B io l. C hem. 2005, 280, 6950-6959.
142. Linsdell, P.; Hanrahan, J.W. Glutathione permeability of cftr. A m. J. P h y sio l. 1998, 275, C323-C326.
143. Cheung, J.C.; Kim Chiaw, P.; Pasyk, S.; Bear, C.E. Molecular basis for the atpase activity of cftr. Arch. Biochem. Biophys. 2008, 476, 95-100.
144. Gadsby, D.C.; Nairn, A.C. Control of cftr channel gating by phosphorylation and nucleotide hydrolysis. Physiol. Rev. 1999, 79, S77-S107.
145. McDonald, R.A.; Matthews, R.P.; Idzerda, R.L.; McKnight, G.S. Basal expression of the cystic fibrosis transmembrane conductance regulator gene is dependent on protein kinase a activity. Proc. Natl. Acad. Sci. USA 1995, 92, 7560-7564.
146. Hanigan, M.H. Expression of gamma-glutamyl transpeptidase provides tumor cells with a selective growth advantage at physiologic concentrations of cyst(e)ine. C a r ci nog en esi s 1995, 16, 181-185.
147. Lu, S.C. Regulation of hepatic glutathione synthesis: Current concepts and controversies. F A SE B J. 1999, 13, 1169-1183.
148. Hochwald, S.N.; Harrison, L.E.; Rose, D.M.; Anderson, M.; Burt, M.E. Gamma-glutamyl transpeptidase mediation of tumor glutathione utilization in vivo. J. Natl. Cancer Inst. 1996, 88, 193-197.
149. Stole, E.; Smith, T.K.; Manning, J.M.; Meister, A. Interaction of gamma-glutamyl transpeptidase with acivicin. J. B iol. C hem. 1994, 269, 21435-21439.
150. Kroemer, G.; Reed, J.C. Mitochondrial control of cell death. Nat. Med. 2000, 6, 513-519.
151. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy. N at. Rev. D rug D iscov. 2010, 9, 447-464.
152. Arai, M.; Imai, H.; Koumura, T.; Yoshida, M.; Emoto, K.; Umeda, M.; Chiba, N.; Nakagawa, Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase plays a major role in preventing oxidative injury to cells. J. B io l. C hem. 1999, 274, 4924-4933.
153. Warburg, O. On the origin of cancer cells. Science 1956, 123, 309-314.
154. Dang, C.V. Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells? Cell Cycle 2010, 9, 3884-3886.
155. DeBerardinis, R.J.; Cheng, T. Q's next: The diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2009, 29, 313-324.
156. Medina, M.A. Glutamine and cancer. J. Nutr. 2001, 131, 2539S-2542S; discussion 2550S-2531S.
157. Wise, D.R.; Thompson, C.B. Glutamine addiction: A new therapeutic target in cancer. Trends Biochem. Sci. 2010, 35, 427-433.
158. Carrascosa, J.M.; Martinez, P.; Nunez de Castro, I. Nitrogen movement between host and tumor in mice inoculated with ehrlich ascitic tumor cells. Can cer R es. 1984, 44, 3831-3835.
159. Carretero, J.; Obrador, E.; Pellicer, J.A.; Pascual, A.; Estrela, J.M. Mitochondrial glutathione depletion by glutamine in growing tumor cells. F ree Radic. B iol. M ed. 2000, 29, 913-923.
160. Wise, D.R.; DeBerardinis, R.J.; Mancuso, A.; Sayed, N.; Zhang, X.Y.; Pfeiffer, H.K.; Nissim, I.; Daikhin, E.; Yudkoff, M.; McMahon, S.B.; Thompson, C.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. P r o c. Natl. Acad. Sci. USA 2008, 105, 18782-18787.
161. Klimberg, V.S.; McClellan, J.L. Organ, C.H., Jr. Honorary lectureship. Glutamine, cancer, and its therapy. Am. J. Surg. 1996, 172, 418-424.
162. Klimberg, V.S.; Souba, W.W.; Dolson, D.J.; Salloum, R.M.; Hautamaki, R.D.; Plumley, D.A.; Mendenhall, W.M.; Bova, F.J.; Khan, S.R.; Hackett, R.L.; et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. C ancer 1990, 66, 62-68.
163. Ziegler, T.R.; Benfell, K.; Smith, R.J.; Young, L.S.; Brown, E.; Ferrari-Baliviera, E.; Lowe, D.K.; Wilmore, D.W. Safety and metabolic effects of l-glutamine administration in humans. J P E N J. Parenter Enteral Nutr. 1990, 14, 137S-146S.
164. Savarese, D.M.; Savy, G.; Vahdat, L.; Wischmeyer, P.E.; Corey, B. Prevention of chemotherapy and radiation toxicity with glutamine. C ancer Treat. Rev. 2003, 29, 501-513.
165. Melis, G.C.; ter Wengel, N.; Boelens, P.G.; van Leeuwen, P.A. Glutamine: Recent developments in research on the clinical significance of glutamine. Curr. Opin. Clin. Nutr. M etab. Care 2004, 7, 59-70.
166. Kuhn, K.S.; Muscaritoli, M.; Wischmeyer, P.; Stehle, P. Glutamine as indispensable nutrient in oncology: Experimental and clinical evidence. Eu r. J. N ut r. 2010, 49, 197-210.
167. Brosnan, J.T. Interorgan amino acid transport and its regulation. J. Nutr. 2003, 133, 2068S-2072S.
168. Goossens, V.; Grooten, J.; Fiers, W. The oxidative metabolism of glutamine. A modulator of reactive oxygen intermediate-mediated cytotoxicity of tumor necrosis factor in l929 fibrosarcoma cells. J. Biol. Chem. 1996, 271, 192-196.
169. Benlloch, M.; Mena, S.; Ferrer, P.; Obrador, E.; Asensi, M.; Pellicer, J.A.; Carretero, J.; Ortega, A.; Estrela, J.M. Bcl-2 and mn-sod antisense oligodeoxynucleotides and a glutamine-enriched diet facilitate elimination of highly resistant b16 melanoma cells by tumor necrosis factor-alpha and chemotherapy. J. Biol. Chem. 2006, 281, 69-79.
170. Dalton, W. Cancer: Principles and Practice of Oncology; De Vita, V.T., Jr., Hellman, S., Rosenberg, S.A., Eds.; J. B. Lippincott: Philadelphia, PA, USA, 1993.
171. Hidalgo, M.; Rodriguez, G.; Kuhn, J.G.; Brown, T.; Weiss, G.; MacGovren, J.P.; Von Hoff, D.D.; Rowinsky, E.K. A phase i and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. Cli n. C ancer Res. 1998, 4, 2763-2770.
172. Moreira, J.N.; Santos, A.; Simoes, S. Bcl-2-targeted antisense therapy (oblimersen sodium): Towards clinical reality. Rev. Recent C lin. Trials 2006, 1, 217-235.
173. Zhang, C.; Pei, J.; Kumar, D.; Sakabe, I.; Boudreau, H.E.; Gokhale, P.C.; Kasid, U.N. Antisense oligonucleotides: Target validation and development of systemically delivered therapeutic nanoparticles. Methods M ol. Biol. 2007, 361, 163-185.
174. Kang, M.H.; Reynolds, C.P. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15, 1126-1132.
175. Dias, N.; Stein, C.A. Potential roles of antisense oligonucleotides in cancer therapy. The example of bcl-2 antisense oligonucleotides. Eu r. J. P harm. B iophar m. 2002, 54, 263-269.
176. Bedikian, A.Y.; Millward, M.; Pehamberger, H.; Conry, R.; Gore, M.; Trefzer, U.; Pavlick, A.C.; DeConti, R.; Hersh, E.M.; Hersey, P.; Kirkwood, J.M.; Haluska, F.G. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group. J. Clin. Oncol. 2006, 24, 4738-4745.
177. Miyake, H.; Tolcher, A.; Gleave, M.E. Antisense bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the shionogi tumor model. C ancer Res. 1999, 59, 4030-4034.
178. Gleave, M.E.; Miayake, H.; Goldie, J.; Nelson, C.; Tolcher, A. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. U rology 1999, 54, 36-46.
179. Zangemeister-Wittke, U.; Schenker, T.; Luedke, G.H.; Stahel, R.A. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br. J. C ancer 1998, 78, 1035-1042.
180. Lopes de Menezes, D.E.; Hudon, N.; McIntosh, N.; Mayer, L.D. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide g3139 combined with free and liposomal doxorubicin. Cli n. Can cer R es. 2000, 6, 2891-2902.
181. Klasa, R.J.; Bally, M.B.; Ng, R.; Goldie, J.H.; Gascoyne, R.D.; Wong, F.M. Eradication of human non-hodgkin's lymphoma in scid mice by bcl-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Cli n. C ancer Res. 2000, 6, 2492-2500.
182. Gjertsen, B.T.; Bredholt, T.; Anensen, N.; Vintermyr, O.K. Bcl-2 antisense in the treatment of human malignancies: A delusion in targeted therapy. Cu rr. P harm. B iotechnol. 2007, 8, 373-381.